Meeting
2017 ASCO Annual Meeting
Expansion study of ADI-PEG 20, pemetrexed and cisplatin in patients with ASS1-deficient malignant pleural mesothelioma (TRAP).
Authors
Melissa Phillips
St Bartholomew's Hospital, London, United Kingdom
Melissa Phillips , Teresa Szyszko , Peter Hall , Gary J. R. Cook , Ramsay Khadeir , Jeremy P. C. Steele , James F. Spicer , Xiaoxing Feng , Mirela Hategan , Sukaina Rashid , Amanda Johnston , John S. Bomalaski , Jonathan Shamash , Simon Pacey , Michael Sheaff , Peter Wojciech Szlosarek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Clinical Trial Registration Number
NCT02029690
Citation
J Clin Oncol 35, 2017 (suppl; abstr 8553)
DOI
10.1200/JCO.2017.35.15_suppl.8553
Abstract #
8553
Poster Bd #
289
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer.
First Author: Peter Wojciech Szlosarek
Poster
2019 ASCO Annual Meeting
Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1 (ASS1)–deficient non-squamous non-small cell lung cancer.
First Author: Akhila Ganeshi Wimalasingham
Poster
2018 ASCO Annual Meeting
Phase 1 study of pegargiminase combined with cisplatin and pemetrexed in patients with ASS1-deficient uveal melanoma.
First Author: Pui Ying Chan
Poster
2016 ASCO Annual Meeting
18-FLT-PET/CT as an imaging biomarker in patients with ASS1-deficient thoracic cancers treated with ADI-PEG20, pemetrexed and cisplatin.
First Author: Peter Wojciech Szlosarek